| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | pac-1 | GDSC1000 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0024 | 0.9 |
| mRNA | TG-100-115 | CTRPv2 | pan-cancer | AAC | 0.0025 | 0.9 |
| mRNA | SB 505124 | GDSC1000 | pan-cancer | AAC | -0.0024 | 0.9 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | 0.003 | 1 |
| mRNA | XMD8-85 | GDSC1000 | pan-cancer | AAC | 0.0035 | 1 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | -0.0022 | 1 |
| mRNA | betulinic acid | CTRPv2 | pan-cancer | AAC | -0.0023 | 1 |
| mRNA | AEW541 | CCLE | pan-cancer | AAC | -0.0027 | 1 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | 0.0021 | 1 |